The animals were intratibially injected with prostate cancer (LuCaP 23.1) cells and subcutaneously administered with osteoprotegerin human recombinant protein (Fc-OPG) (6.0 mg/kg) thrice a week, either 24 h pre-injection or four weeks post-injection. Here, TNFRSF11B is linked to prostate cancer.